Skip to content

SMART - Systems Medicine of Heart Failure

Smart - Systems Medicine of Heart Failure

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03172338
Enrollment
60
Registered
2017-06-01
Start date
2015-06-02
Completion date
2018-02-28
Last updated
2017-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Disease

Brief summary

The onset and course of heart failure (HF) is triggered by a complex regulatory network that includes stressors (pressure overload by individual anatomic hemodynamic settings), intrinsic (genes), environmental (regulating epigenetics), and modifying factors (such as hor-mones and the immune system). SMART aims to establish individualized strategies for the prevention and management of HF by early detection of the physiological, genomic, proteo-mic and hemodynamic mechanisms that lead from onecommon cause of ventricular dysfunction (pressure overload) to maladaptive remodelling and irreversible HF. To cope with the complexity of HF, SMART will interrelate models describing the interplay between ge-nome, proteome and cell function, regulating hormones, tissue composition and hemody-namic whole organ function up to a whole body description of a patient and patient cohorts. The ultimate goal is to demonstrate proof-of-concept tools for predicting disease evolution and efficacy of treatment in a given patient. To achieve this task SMART will apply * A modelling framework that couples multi-scale mechanistic models with in-depth genome/proteome, cell physiology and whole organ (biomechanical and fluid dynamic) models * Subsequently, investigate methods validity and relevance for quantitative prediction of treatment outcome in a clinical proof-of-concept trial (demonstrator) of patients with aortic valve desieases.

Interventions

None listed

Sponsors

German Heart Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Aortic Valve Stenosis

Exclusion criteria

* coronary heart disease

Design outcomes

Primary

MeasureTime frameDescription
Hypertrophy3 monthsMuscle Mass and Fibrosis

Countries

Germany

Contacts

Primary ContactSarah Nordmeyer, MD
snordmeyer@dhzb.de0049 30 45932800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026